News | February 08, 2021
Zydus completes enrolment for two Phase Ill trials of Desidustat
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
Subscribe To Our Newsletter & Stay Updated
